Mahesh K B Parmar

发表

Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data

Patrick Royston, Jayne F Tierney, Yinghui Wei, 2015, Statistics in medicine.

A simulation study of predictive ability measures in a survival model II: explained randomness and predictive accuracy

P Royston, Mahesh K B Parmar, P. Royston, 2012, Statistics in medicine.

A phase 3 trial of bevacizumab in ovarian cancer.

Jacobus Pfisterer, Jalid Sehouli, Rainer Kimmig, 2011, The New England journal of medicine.

Outcomes and endpoints in cancer trials: bridging the divide.

Katherine Karakasis, Deborah Collyar, Ian F Tannock, 2015, The Lancet. Oncology.

Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer

Patrick Royston, Mahesh K B Parmar, P. Royston, 2003, Statistics in medicine.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Noel W Clarke, Gerhardt Attard, Nicholas D James, 2014, European urology.

Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer

Patrick Royston, Richard Sylvester, Mahesh K B Parmar, 2004, Statistics in medicine.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Jacobus Pfisterer, Gordon C Jayson, Michael Quinn, 2015, The Lancet. Oncology.

A simulation study of predictive ability measures in a survival model I: Explained variation measures

Patrick Royston, Babak Choodari-Oskooei, Mahesh K B Parmar, 2012, Statistics in medicine.